Ivan Che­ung's post-Ei­sai life takes hold at Next­Point Ther­a­peu­tics; Sanofi, Take­da an­nounce CFO ex­its

Ivan Che­ung, who led Ei­sai’s US busi­ness and was a cen­tral fig­ure in the biotech’s Alzheimer’s work, has stepped in­to the CEO po­si­tion at a Cam­bridge, MA start­up.

He start­ed run­ning im­muno-on­col­o­gy out­fit Next­Point Ther­a­peu­tics last month, hav­ing de­part­ed Ei­sai short­ly af­ter Ei­sai se­cured full FDA ap­proval for its Alzheimer’s treat­ment Leqem­bi last sum­mer. The 30-em­ploy­ee up­start has reeled in back­ing from Big Phar­mas like Sanofi and Bay­er, as well as VC firms like MPM Cap­i­tal and Catalio Cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.